<DOC>
	<DOCNO>NCT00272909</DOCNO>
	<brief_summary>This research study design evaluate safety , tolerability , efficacy SUN N4057 ( piclozotan ) subject acute ischemic stroke within 9 hour onset symptom .</brief_summary>
	<brief_title>Efficacy SUN N4057 Subjects With Acute Ischemic Stroke Measurable Penumbra Magnetic Resonance Imaging ( MRI )</brief_title>
	<detailed_description>The primary objective study determine efficacy 72 hour infusion SUN N4057 ( piclozotan ) subject clinical finding acute ischemic stroke magnetic resonance imaging ( MRI ) demonstrate measurable penumbra ( perfusion-weighted imaging [ PWI ] minus diffusion-weighted imaging [ DWI ] volume ) . Efficacy determine compare proportion subject growth stroke lesion volume assess DWI Screening stroke lesion volume assess FLAIR ( fluid-attenuated inversion recovery ) Day 28 piclozotan group versus placebo group .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Piclozotan</mesh_term>
	<criteria>General inclusion criterion : Males female &gt; = 18 &lt; = 85 year age randomization . Female subject must either : Surgically sterile ; Postmenopausal least 1 year ; Nonpregnant , confirm serum pregnancy test , use method birth control acceptable investigator . Neurological examination demonstrate localize cortical sign Receipt study drug le 6 hour ( 50 % subject ) 6 9 hour , inclusive , ( 50 % subject ) onset symptom ( unwitnessed stroke , last time see normal state bedtime unwitnessed stroke sleep ) Signed informed consent subject legally acceptable representative NIHSS score 6 22 , inclusive , least 2 aphasia item NIHSS location MRI finding consistent aphasia MRIdetermined inclusion criterion : Acute ischemic stroke substantial cortical involvement middle cerebral artery ( MCA ) distribution , verify Screening DWI abnormality and/or Screening PWI abnormality . ( Note : white matter involvement , addition cortex , exclusion . ) General exclusion criterion : Two following : Reduced level consciousness ( score &gt; = 2 NIHSS Q1a ) Forced eye deviation total gaze paresis ( score 2 NIHSS Q2 ) Dense hemiplegia ( movement ) upper low extremity ( score 4 NIHSS Q5 regard motor arm score 4 NIHSS Q6 regard motor leg ) Prestroke modify Rankin score &gt; = 2 Screening Rapid neurological improvement Screening start drug infusion Persistent systolic blood pressure ( SBP ) &gt; 220 mmHg and/or diastolic blood pressure ( DBP ) &gt; 120 mmHg ( confirm least three reading take least 3 minute apart ) prior randomization . If subsequent reading consistently level , either spontaneously follow mild antihypertensive therapy , subject may enrol . MRIdetermined exclusion criterion : Intracranial hemorrhage verify Screening MRI . ( Note : intracranial hemorrhage prescreen computerize tomography [ CT ] scan also exclude subject . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Acute Ischemic Stroke</keyword>
	<keyword>9-Hour window MRI</keyword>
	<keyword>Serotonin receptor agonist</keyword>
</DOC>